Header Logo

Connection

Philip Bonomi to Administration, Intravenous

Back to Details
This is a "connection" page, showing publications Philip Bonomi has written about Administration, Intravenous.
Philip Bonomi
Connection Strength
0.037
Administration, Intravenous
  1. An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). Lung Cancer. 2017 02; 104:126-130.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.